Simultaneous Detection of Ubiquinol and Ubiquinone in Human Plasma as a Marker of Oxidative Stress

Yamashita, Satoshi; Yamamoto, Yorihiro

doi:10.1006/abio.1997.2187

Cited by 203 publications

(139 citation statements)

References 20 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…The baseline and follow-up samples were analyzed by 1 analytical line. Simultaneous detection of ubiquinol-10 and ubiquinone-10 was performed utilizing the method of Yamashita and Yamamoto (10). Briefly, human serum was mixed with 5 vol.…”

Section: Laboratory Methodsmentioning

confidence: 99%

Reduction of Serum Ubiquinol-10 and Ubiquinone-10 Levels by Atorvastatin in Hypercholesterolemic Patients

Mabuchi

Higashikata

Kawashiri

et al. 2005

JAT

107

View full text Add to dashboard Cite

Reduction of serum cholesterol levels with statin therapy decreases the risk of coronary heart disease. Inhibition of HMG-CoA reductase by statin results in decreased synthesis of cholesterol and other products downstream of mevalonate, which may produce adverse effects in statin therapy. We studied the reductions of serum ubiquinol-10 and ubiquinone-10 levels in hypercholesterolemic patients treated with atorvastatin. Fourteen patients were treated with 10 mg/day of atorvastatin, and serum lipid, ubiquinol-10 and ubiquinone-10 levels were measured before and after 8 weeks of treatment. Serum total cholesterol and LDL-cholesterol levels decreased significantly. All patients showed definite reductions of serum ubiquinol-10 and ubiquinone-10 levels, and mean levels of serum ubiquinol-10 and ubiquinone-10 levels decreased significantly from 0.81 ± ± ± ± ± 0.21 to 0.46 ± ± ± ± ± 0.10 µ µ µ µ µg/ml (p < 0.0001), and from 0.10 ± ± ± ± ± 0.06 to 0.06 ± ± ± ± ± 0.02 µ µ µ µ µg/ml (p = 0.0008), respectively. Percent reductions of ubiquinol-10 and those of total cholesterol showed a positive correlation (r = 0.627, p = 0.0165). As atorvastatin reduces serum ubiquinol-10 as well as serum cholesterol levels in all patients, it is imperative that physicians are forewarned about the risks associated with ubiquinol-10 depletion. J Atheroscler Thromb, 2005; 12: 111-119.

show abstract

Section: Laboratory Methodsmentioning

confidence: 99%

Reduction of Serum Ubiquinol-10 and Ubiquinone-10 Levels by Atorvastatin in Hypercholesterolemic Patients

Mabuchi

Higashikata

Kawashiri

et al. 2005

JAT

107

View full text Add to dashboard Cite

show abstract

“…There are two major forms of CoQ10; reduced ubiquinol (CoQ10H) and oxidized (CoQ10). The high rate of CoQ10/CoQ10H or high level of oxidized CoQ10 is an important indicator in determining mitochondrial membrane damage (25,26). Until now, there are no studies that show the mitochondrial membrane damage in stored blood.…”

Section: Discussionmentioning

confidence: 99%

In Stored Human Blood, The Inhibitor Effect of Tannic Acid and Caffeic Acid on Lipid Peroxidation and Oxidative DNA Damage

Huyut¹,

Şekeroğlu²,

Balahoroğlu³

et al. 2016

Eastern J Med

View full text Add to dashboard Cite

“…However, ubiquinol represents 80-85% of the total CoQ10 pool in human plasma. 34) Therefore, the level of total CoQ10 is likely to reflect the level of ubiquinol. Study limitations: The present study was limited for several reasons.…”

Section: Discussionmentioning

confidence: 99%

Atorvastatin-Induced Changes in Plasma Coenzyme Q10 and Brain Natriuretic Peptide in Patients With Coronary Artery Disease

et al. 2008

View full text Add to dashboard Cite

SUMMARYThe beneficial effects of statins in patients with coronary artery disease (CAD) may be balanced by concerns that statins can depress production of ubiquinone (CoQ10), which serves as a component of mitochondrial energy production and an antioxidant. Accordingly, the effects of atorvastatin (ATO)-induced changes in plasma CoQ10 on BNP and oxidative stress were investigated. In 29 patients with CAD, the plasma levels of CoQ10 and BNP and urinary excretion of 8-iso-prostaglandin F2α (8-iso-PGF) were determined before and after 3-month treatment with ATO. Ten patients had received pravastatin and 10 patients fluvastatin, while 9 patients had not received any statin before ATO. There was a linear correlation between ATO-induced changes in total cholesterol and CoQ10 (r = 0.632, P < 0.01), and an inverse correlation between ATO-induced changes in CoQ10 and BNP (r = -0.497, P < 0.01). There was no significant correlation between ATO-induced changes in CoQ10 and 8-iso-PGF. Multivariate analysis revealed that ATO-induced decreases in plasma CoQ10 were significantly associated with increasing BNP levels. In conclusion, long-term treatment with ATO might increase plasma levels of BNP in patients with CAD when it is accompanied by a greater reduction in plasma CoQ10. However, ATO-induced decreases in CoQ10 might not increase oxidative stress. (Int Heart J 2008; 49: 423-433)

show abstract

Simultaneous Detection of Ubiquinol and Ubiquinone in Human Plasma as a Marker of Oxidative Stress

Cited by 203 publications

References 20 publications

Reduction of Serum Ubiquinol-10 and Ubiquinone-10 Levels by Atorvastatin in Hypercholesterolemic Patients

Reduction of Serum Ubiquinol-10 and Ubiquinone-10 Levels by Atorvastatin in Hypercholesterolemic Patients

In Stored Human Blood, The Inhibitor Effect of Tannic Acid and Caffeic Acid on Lipid Peroxidation and Oxidative DNA Damage

Atorvastatin-Induced Changes in Plasma Coenzyme Q10 and Brain Natriuretic Peptide in Patients With Coronary Artery Disease

Contact Info

Product

Resources

About